Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center
Background and aims: Prostatic urethral lift (Urolift™) is a minimally invasive technique to treat male lower urinary tract symptoms (LUTSs) due to benign prostatic hyperplasia (BPH). The aim of the present study was to assess safety and medium- to long-term outcomes in the relief of urinary symptom...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-07-01
|
Series: | Therapeutic Advances in Urology |
Online Access: | https://doi.org/10.1177/17562872211037109 |
id |
doaj-545dd73d0627485889b999f4ccd72cfc |
---|---|
record_format |
Article |
spelling |
doaj-545dd73d0627485889b999f4ccd72cfc2021-07-31T21:34:02ZengSAGE PublishingTherapeutic Advances in Urology1756-28802021-07-011310.1177/17562872211037109Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single centerPasquale AnneseNicola d’AltiliaVito ManciniUgo G. FalagarioFrancesco Del GiudiceMatteo FerroOttavio de CobelliAngelo PorrecaGian Maria BusettoGiuseppe CarrieriBackground and aims: Prostatic urethral lift (Urolift™) is a minimally invasive technique to treat male lower urinary tract symptoms (LUTSs) due to benign prostatic hyperplasia (BPH). The aim of the present study was to assess safety and medium- to long-term outcomes in the relief of urinary symptoms. Methods: We included 35 men, affected by severe symptomatic BPH evaluated by International Prostate Symptom Score (IPSS), with normal erectile function (EF) and ejaculatory function (EjF) evaluated by the International Index of Erectile Dysfunction (IIEF-5) and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD-SF). Exclusion criteria were prostate larger than 70 cm 3 , bladder neck sclerosis, concomitant third prostatic lobe, and/or other cervical urethral obstruction or cancer. All patients, preoperatively, performed uroflowmetry (UFM) with peak flow (Q-max) and post void residual volume (PVR), digital rectal exam, transrectal prostate ultrasound to measure prostate volume, PSA, and cystoscopy. Follow-up was scheduled at 1–3–6 months, then yearly, evaluating UFM, IPSS, IIEF-5, and MSHQ-EjD-SF. Results: All procedures were performed by a single senior surgeon and follow-up was 33.8 ± 12 months. Preoperative PSA was 0.82 ± 0.4 ng/ml and mean operative time was 19.6 ± 10 min and 3 (2–4) implants per patient were used. Parameters reported at last follow-up schedule were: Q-max increase of 68% ( p = 0.001), PVR reduction 68% ( p = 0.005), and IPSS reduction 55% ( p < 0.0001). EF and EjF were similarly preserved, and no patients presented retrograde ejaculation. A total of 88.6% of patients were satisfied with LUTSs improvement and 100% satisfied with EjF. Conclusion: Urolift can improve urinary disorders secondary to BPH, preserving EjF and EF. It is a safe and easy method, reproducible, and with low incidence of complications. Careful selection of patients is mandatory. The main reason for dissatisfaction is the higher expectation of better BPH symptoms relief although patients with high bladder neck and/or prostate volume >45 cm 3 were aware of the possible failure.https://doi.org/10.1177/17562872211037109 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pasquale Annese Nicola d’Altilia Vito Mancini Ugo G. Falagario Francesco Del Giudice Matteo Ferro Ottavio de Cobelli Angelo Porreca Gian Maria Busetto Giuseppe Carrieri |
spellingShingle |
Pasquale Annese Nicola d’Altilia Vito Mancini Ugo G. Falagario Francesco Del Giudice Matteo Ferro Ottavio de Cobelli Angelo Porreca Gian Maria Busetto Giuseppe Carrieri Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center Therapeutic Advances in Urology |
author_facet |
Pasquale Annese Nicola d’Altilia Vito Mancini Ugo G. Falagario Francesco Del Giudice Matteo Ferro Ottavio de Cobelli Angelo Porreca Gian Maria Busetto Giuseppe Carrieri |
author_sort |
Pasquale Annese |
title |
Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center |
title_short |
Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center |
title_full |
Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center |
title_fullStr |
Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center |
title_full_unstemmed |
Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center |
title_sort |
preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Urology |
issn |
1756-2880 |
publishDate |
2021-07-01 |
description |
Background and aims: Prostatic urethral lift (Urolift™) is a minimally invasive technique to treat male lower urinary tract symptoms (LUTSs) due to benign prostatic hyperplasia (BPH). The aim of the present study was to assess safety and medium- to long-term outcomes in the relief of urinary symptoms. Methods: We included 35 men, affected by severe symptomatic BPH evaluated by International Prostate Symptom Score (IPSS), with normal erectile function (EF) and ejaculatory function (EjF) evaluated by the International Index of Erectile Dysfunction (IIEF-5) and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD-SF). Exclusion criteria were prostate larger than 70 cm 3 , bladder neck sclerosis, concomitant third prostatic lobe, and/or other cervical urethral obstruction or cancer. All patients, preoperatively, performed uroflowmetry (UFM) with peak flow (Q-max) and post void residual volume (PVR), digital rectal exam, transrectal prostate ultrasound to measure prostate volume, PSA, and cystoscopy. Follow-up was scheduled at 1–3–6 months, then yearly, evaluating UFM, IPSS, IIEF-5, and MSHQ-EjD-SF. Results: All procedures were performed by a single senior surgeon and follow-up was 33.8 ± 12 months. Preoperative PSA was 0.82 ± 0.4 ng/ml and mean operative time was 19.6 ± 10 min and 3 (2–4) implants per patient were used. Parameters reported at last follow-up schedule were: Q-max increase of 68% ( p = 0.001), PVR reduction 68% ( p = 0.005), and IPSS reduction 55% ( p < 0.0001). EF and EjF were similarly preserved, and no patients presented retrograde ejaculation. A total of 88.6% of patients were satisfied with LUTSs improvement and 100% satisfied with EjF. Conclusion: Urolift can improve urinary disorders secondary to BPH, preserving EjF and EF. It is a safe and easy method, reproducible, and with low incidence of complications. Careful selection of patients is mandatory. The main reason for dissatisfaction is the higher expectation of better BPH symptoms relief although patients with high bladder neck and/or prostate volume >45 cm 3 were aware of the possible failure. |
url |
https://doi.org/10.1177/17562872211037109 |
work_keys_str_mv |
AT pasqualeannese preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT nicoladaltilia preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT vitomancini preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT ugogfalagario preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT francescodelgiudice preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT matteoferro preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT ottaviodecobelli preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT angeloporreca preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT gianmariabusetto preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter AT giuseppecarrieri preservingejaculatoryfunctioninyoungpatientswithlowerurinarytractsymptomsmediumtolongtermfollowupofprostaticurethralliftatasinglecenter |
_version_ |
1721246500598579200 |